FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
ORIGINAL SOURCE →via FDA News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · health
- [HEALTH] Knowledge, Attitudes, and Practices Regarding Arboviruses at a Human-Wildlife Interface: A Cross-Sectional Study in and
- [HEALTH] How to shore up trust during the "cold-period" between pandemics - closing the public trust gap in pandemic preparedness
- [HEALTH] Trk1 potassium transport is crucial for effective Candidozyma auris skin colonization.
- [HEALTH] [A rapid visual detection method for porcine circovirus type 4 based on enzymatic recombinase amplification and CRISPR/E
- [HEALTH] Genetic clues in 3,000 Indians reveal new lipid routes to cardiometabolic disease
- [HEALTH] Paxlovid looked like a COVID game-changer, but in vaccinated adults the real story is far more complicated